Fly News Breaks for February 17, 2020
Feb 17, 2020 | 13:16 EDT
Citi analyst Andrew Baum downgraded Novartis to Neutral from Buy with a CHF 103 price target. The company's ability to fend off generic competition for multiple sclerosis drug Gilenya in the U.S. is now largely priced into the shares, Baum tells investors in a research note. Further, the analyst sees limited near-term upside to his already above consensus estimates.
News For NVS From the Last 2 Days